FXN and cardiomyopathy: Intravenous administration of adeno-associated virus (AAV) rh10 vector expressing human frataxin prevented the development of cardiomyopathy, but more importantly, administration after onset of heart failure was able to reverse the cardiomyopathy at functional, cellular, and molecular levels within a few days [34].